PsiOxus Will Seek $50m Series D Financing In H1 2018 To Fund Pipeline
Executive Summary
PsiOxus Therapeutics' CEO tells Scrip it will seek the fresh funding next year to progress its pipeline which aims to treat solid tumors through systemic delivery of oncolytic viruses.
You may also be interested in...
Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight
The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.